BTIG’s Richard Greenfield praises the TWTR management’s team savvy efforts to realize a “far more engaged user base.”
Wall Street is paying attention to FBR’s George Zavoico’s surge in enthusiasm on Novavax’s prospects.
Mizuho’s Irina Rivkind Koffler is leaving the sidelines on Teba and boosting her price target, now angling for 19% upside.
Canaccord’s Mark Massaro is impressed that even after recent HTGM share volatility, the healthcare player still delivered an impressive robust fourth quarter turnout for 2017.
Maxim’s Brian Kinstlinger: The recent capital raise is a significant positive event for NXTD.
J.P.
MKM’s Ruben Roy now sees 27% upside potential for Micron shares ahead of its FQ1 results, believing memory trends are looking mostly positive.
H.C.
Canaccord’s John Newman now sees almost 18% in upside potential for SAGE following a big clinical home run in major depressive disorder.
Guggenheim’s Rohit Vanjani puts a price tag on Revance Therapeutics.
